| __timestamp | BioCryst Pharmaceuticals, Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 882000 |
| Thursday, January 1, 2015 | 1896000 | 1361000 |
| Friday, January 1, 2016 | 2699000 | 2058000 |
| Sunday, January 1, 2017 | 1702000 | 3554000 |
| Monday, January 1, 2018 | 471000 | 5215000 |
| Tuesday, January 1, 2019 | 4101000 | 5504000 |
| Wednesday, January 1, 2020 | 1676000 | 5582000 |
| Friday, January 1, 2021 | 7264000 | 5281000 |
| Saturday, January 1, 2022 | 6594000 | 5385000 |
| Sunday, January 1, 2023 | 4661000 | 6481000 |
Unlocking the unknown
In the competitive world of biotechnology, understanding cost structures is crucial. This chart compares the cost of revenue for Corcept Therapeutics Incorporated and BioCryst Pharmaceuticals, Inc. over the past decade. Corcept Therapeutics has consistently maintained a higher cost of revenue, peaking in 2023 with a 6% increase from the previous year. Meanwhile, BioCryst Pharmaceuticals saw a significant spike in 2021, with costs rising by 57% compared to 2020, before stabilizing in subsequent years.
This analysis provides a window into the financial strategies of these two biotech firms, offering valuable insights for investors and industry analysts.
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Corcept Therapeutics Incorporated
Intra-Cellular Therapies, Inc. vs Corcept Therapeutics Incorporated: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Bausch Health Companies Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored